



July 19, 2023

Bonebridge AG
% Dawn Balazs-Metz
Senior Consultant
Meditec Consulting GmbH
Obermoosstrasse 23
Berne, BE 3067
Switzerland

Re: K231292

Trade/Device Name: TAMINA 3.5mm Proximal Humerus System; POYA 3.5MM Lateral Proximal
Tibia System; LORRAINE 3.5mm Distal Humerus System

Regulation Number: 21 CFR 888.3030

Regulation Name: Single/Multiple Component Metallic Bone Fixation Appliances And Accessories

Regulatory Class: Class II

Product Code: HRS, HWC

Dated: May 3, 2023

Received: May 4, 2023

Dear Dawn Balazs-Metz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,


Shumaya Ali -S

Shumaya Ali, M.P.H.

Assistant Director

DHT6C: Division of Restorative, Repair
and Trauma Devices

OHT6: Office of Orthopedic Devices

Office of Product Evaluation and Quality

Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)
K231292

Device Name

TAMINA 3.5mm Proximal Humerus System;
POYA 3.5mm Lateral Proximal Tibia System;
LORRAINE 3.5mm Distal Humerus System

Indications for Use (Describe)

TAMINA 3.5mm Proximal Humerus System

The TAMINA, TAMINA Long and TAMINA-TF Proximal Humerus System is indicated for

- Dislocated two-, three-, and four fragment fractures of the proximal humerus including fractures involving osteopenic bone
- Pseudarthroses (non-unions) of the proximal humerus
- Osteotomies of the proximal humerus

POYA 3.5mm Lateral Proximal Tibia System

The POYA 3.5mm Lateral Proximal Tibia System is indicated for the internal fixation of fractures of the proximal tibia in adults and skeletally mature adolescents including:

- simple fractures
- comminuted fractures
- lateral wedge, medial wedge as well as bicondylar combination of lateral and medial wedge fractures
- depression fractures
- periprosthetic fractures
- nonunions, malunions, tibial osteotomies and osteopenic bone
- fractures with associated shaft fractures

LORRAINE 3.5mm Distal Humerus System

The LORRAINE 3.5mm Distal Humerus System is indicated for intra-articular or extra-articular fractures of the distal humerus, supracondylar fractures, osteotomies, and non-unions. Longer plates may be used for distal humerus fractures with diaphyseal extension.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary K231292

In accordance with 21 CFR 807.92 the following information is provided for the Bonebridge Osteosynthesis Plating System.

ADMINISTRATIVE INFORMATION

Date prepared	July 07, 2023
Submission type:	Traditional 510(k)
Purpose of 510(k):	Modification of currently cleared device K213864 Line extension of the cleared K213864 TAMINA 3.5mm Proximal Humerus System and POYA 3.5mm Lateral Proximal Tibia System and introduction of an additional plating system LORRAINE 3.5mm Distal Humerus System A proposed modification to harmonize contraindications of the cleared (K213864) TAMINA 3.5mm Proximal Humerus System and POYA 3.5mm Lateral Proximal Tibia System Announcement of minor modifications to the device since the last clearance (K213864)
Submitter	Bonebridge AG Bahnhofstrasse 11 6300 Zug Switzerland
Official Contact	Michelle Gumpelmayer Head of QM & RA, Bonebridge AG
Alternative Contact	Dawn Balazs-Metz Senior consultant, meditec Consulting GmbH Phone: +41 79 772 5540 Email balazs-metz@meditec-consulting.ch
US agent	Viky Verna, confinis corporation Email: viky.verna@confinis.com

DEVICE NAME AND CLASSIFICATION

Trade name:	Bonebridge Osteosynthesis Plating System
Variants, types:	TRIFT 3.5mm 1/3 Tubular System SALGINA 2.5mm Volar Distal Radius System CASCELLA 3.5mm Superior Clavicle System TAMINA 3.5mm Proximal Humerus System POYA 3.5mm Lateral Proximal Tibia System POYA 3.5mm Posteromedial Tibia System

DALVAZZA 2.5mm Distal Ulna System
LEPORELLO 3.5mm Olecranon System
LORRAINE 3.5mm Distal Humerus System

Common name: Plate, Fixation, Bone
Screw, Fixation, Bone

Regulation number: 21 CFR 888.3030 (primary),
21 CFR 888.3040

Classification name: Single/multiple component metallic bone fixation
appliances and accessories (primary),
Smooth or threaded metallic bone fixation fastener

Regulatory class: Class II

Product Code: HRS (primary), HWC

PREDICATE DEVICES

Primary predicate device: Bonebridge Osteosynthesis Plating System (K213864)
TAMINA 3.5mm Proximal Humerus System

Additional predicate devices:

TAMINA 3.5mm Proximal Humerus System	K041860 Synthes (USA) LCP® Proximal Humerus Plates, Long K011815 Synthes LCP Proximal Humerus Plates K082807 Synthes (USA) 3.5mm and 4.5mm Locking Compression Plate (LCP) System with Expanded Indications
POYA 3.5mm Lateral Proximal Tibia System (POYA-L)	K120689 SYNTHES 3.5 mm Variable Angle LCP Proximal Tibia Plate system K082807 Synthes (USA) 3.5mm and 4.5mm Locking Compression Plate (LCP) System with Expanded Indications
LORRAINE 3.5mm Distal Humerus System	K120070 Synthes Variable Angle LCP Elbow System / Distal Humerus Plates K101056 VariAx Elbow System / Distal Humerus Plates K082807 Synthes (USA) 3.5mm and 4.5mm Locking Compression Plate (LCP) System with Expanded Indications

INDICATIONS FOR USE

TAMINA 3.5mm Proximal Humerus System

The TAMINA, TAMINA Long and TAMINA-TF Proximal Humerus System is indicated for:

- Dislocated two-, three-, and four fragment fractures of the proximal humerus including fractures involving osteopenic bone.
- Pseudarthroses (non-unions) of the proximal humerus
- Osteotomies of the proximal humerus

POYA 3.5mm Lateral Proximal Tibia System

The POYA 3.5mm Lateral Proximal Tibia System is indicated for the internal fixation of fractures of the proximal tibia in adults and skeletally mature adolescents including:

- simple fractures
- comminuted fractures
- lateral wedge, medial wedge as well as bicondylar combination of lateral and medial wedge fractures
- depression fractures
- periprosthetic fractures
- nonunions, malunions, tibial osteotomies and osteopenic bone
- fractures with associated shaft fractures

LORRAINE 3.5mm Distal Humerus System

The LORRAINE 3.5mm Distal Humerus System is indicated for intra-articular or extra-articular fractures of the distal humerus, supracondylar fractures, osteotomies, and non-unions. Longer plates may be used for distal humerus fractures with diaphyseal extension.

DEVICE DESCRIPTION

The Bonebridge Osteosynthesis Plating System is intended for treating fractures of various bones. It consists of plates, locking and non-locking screws for fixation and corresponding instruments. The plating system is further subdivided into variants/types based on the anatomical location of the fracture.

Plates and screws are made of stainless steel (ISO 5832-1 or ASTM F138 or ASTM F139) or pure titanium (ASTM F67 or ISO 5832-2). All materials used are biocompatible, corrosion-resistant and nontoxic in a biological environment. Surgical instruments are made of stainless steel (ASTM F899, ISO 7153-1, ISO 5832-1, and ASTM F138/139), medical grade PEEK, medical grade EPDM terpolymer, or medical grade silicone.

All plates are sterilized with gamma irradiation and delivered sterile. Screws and instruments are delivered non-sterile. Devices supplied in a non-sterile condition must be cleaned and steam sterilized prior to surgical use. Non-clinical testing has demonstrated the devices are MR Conditional.

SUMMARY OF TECHNOLOGICAL CHARACTERISTICS AND COMPARISON TO PREDICATE DEVICE

The subject device and the predicate devices have the same intended use, similar indications for use, and have the same technological characteristics. The subject and predicate devices are all fabricated from the same or similar materials and share similar design characteristics, including plate screw holes to accommodate locking and non-locking screws. The subject and predicate devices encompass the same range of physical dimensions, and the subject device is compatible with screws from the predicate devices. The subject and predicate devices are sterilized by the standard methods. Any differences in the technological characteristics do not raise new issues of safety or efficacy.

SUMMARY OF NON-CLINICAL TESTS

Sterilization validation:	Gamma irradiation: The minimal dose of 25kGy is validated using VDmax25 method as described in ISO 11137-2 and confirmed a Sterility Assurance Level SAL of 10^{-6} .	Pass
	Steam sterilization: Cleaning and sterilization procedures have been successfully validated in accordance with ISO 17664 and ISO 17665-1 at 132°C (270F) for 4 minutes and 20 min drying time.	
Packaging validation:	Validation of the sterile packaging has been successfully performed in accordance with ISO 11607 1/2 and ASTM F1980. Furthermore, a transport simulation was conducted according ISTA 2A followed by these packaging verification tests: <ul data-bbox="581 1234 1247 1409" style="list-style-type: none">• Dye-Penetration, ASTM F1929• Visual inspection, ASTM F1886/1886M• Seal strength, ASTM F88/F88M• Microbial barrier testing, DIN 58953-6, Chapter 2.14	Pass
Biocompatibility:	Biological Evaluation and toxicological risk assessment to evaluate device's biological safety for the intended use, in accordance with ISO 10993-series.	Pass
	Tests performed: Chemical Characterization, Cytotoxicity and LAL Testing	
Mechanical testing:	Plates: Static and dynamic comparative testing has been performed and included statistical analysis and comparative testing to the predicate devices. Non-inferiority of the Bonebridge device compared to the predicate device with regard to maximum force (static test) and maximum force for a given number of cycles	Pass

(dynamic test). The predefined acceptance criteria were successfully met.

Design verification was successfully completed and included compatibility of implants and instruments as well as assessment of anatomical shape and appearance

MRI safety: The Bonebridge Osteosynthesis Plating System is MR conditional considering local SAR based on the following tests Pass

- Assessment of displacement force and torque effects in the main static magnetic field at 3Tesla. Additionally, the expected magnetic force in a stronger magnetic field gradient of 30T/m was extrapolated. (According to ASTM F2052-21 and ASTM F2213-17)
- Assessment of heating effects due to the RF-field during MR scans at 1.5Tesla and 3Tesla according to ASTM F2182-19
- Assessment of image artifacts at 3Tesla according to ASTM F2119-07 (2013)

The tested implant and associated product family can be claimed as MR conditional.

SUMMARY OF CLINICAL AND USABILITY TESTS

Based on a clinical evaluation including literature review and the results of verification and validation activities it has been concluded that clinical investigations were not required. The summative usability evaluation according to IEC 62366-1 shows that the Bonebridge Osteosynthesis Plating System there are no significant usability issues due to the study acceptance criteria of the primary objectives prior Application/ Usability Risk Assessment update. Therefore, the summative usability evaluation studies of the Bonebridge Osteosynthesis Plating System are considered successful. The study participants were able to use the products safely and effectively.

CONCLUSION

The subject Bonebridge Osteosynthesis Plating System has similar indications, intended use, target populations, technological characteristics, and materials as the predicate devices. Non-clinical testing demonstrated that the performance of the proposed devices is equivalent to the predicate devices.